OBJECTIVE The aim of the study was to investigate a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the determination of rivaroxaban and evaluate the correlation between plasma concentration and anti-Xa activity in patients using oral rivaroxaban. METHODS In this study, the plasma concentration of rivaroxaban and anti-Xa factor activities was determined in 125 patients, and the relationship between the two variables was analysed by SPSS 21.0 software. RESULTS The results showed that the plasma concentrations of oral rivaroxaban patients were significantly correlated with the activity of the anti-Xa factor (Spearman's r = 0.990, P < 0.05). CONCLUSION The plasma concentrations of rivaroxaban are a potentially useful monitoring indicator to assess the patient's bleeding risk if testing for plasma anti-Xa activity is not available.

中文翻译：

---

基于HPLC-MS/MS的利伐沙班与血中Xa因子活性关系的研究。

目的：本研究的目的是研究一种高效液相色谱-串联质谱（HPLC-MS/MS）测定利伐沙班的方法，并评估口服利伐沙班患者血浆浓度与抗Xa活性之间的相关性。方法本研究测定125例患者的血浆利伐沙班浓度和抗Xa因子活性，采用SPSS 21.0软件分析两变量之间的关系。结果结果显示，口服利伐沙班患者的血药浓度与抗Xa因子活性显着相关（Spearman's r = 0.990，P<0.05）。结论 利伐沙班的血浆浓度是评估患者的潜在有用的监测指标。